Clinical Trials Logo

Clinical Trial Summary

Pulmonary rehabilitation programs are part of the multidisciplinary treatment of some chronic respiratory diseases such as COPD (chronic obstructive pulmonary disease). Although clinical guidelines of other diseases such as non-cystic fibrosis bronchiectasis (nCFBE) discuss the benefits of these programs in quality of life and exercise tolerance, evidence of such intervention in nCFBE patients is insufficient. Longer studies are needed with larger sample sizes and optimized to maximize the response and maintain long-term benefits. The present study aims to examine the effects in exercise tolerance of a pulmonary rehabilitation program combined with respiratory physiotherapy in patients with nCFBE. It is a randomized controlled clinical trial with a total duration of 24 months. The intervention will be performed during 12 weeks and then will be a period of 12 months of maintenance. This is a multicenter study involving the following Hospitals: Hospital Clinic, Hospital la Plató and Hospital del Mar of Barcelona, Hospital Josep Trueta of Girona, Royal Infirmary of Edinburgh and Fondazione Maugeri di Lumezzane of Italy. Subjects will be randomized into three groups in a ratio (1: 1: 1) (1) Pulmonary Rehabilitation (2) Chest Physiotherapy and (3) Pulmonary Rehabilitation + Chest Physiotherapy. Hospital la Plató from Barcelona will be responsible for carrying out the Control Group. The primary endpoint will be the test of "endurance shuttle walk test".


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT02614300
Study type Interventional
Source Hospital Clinic of Barcelona
Contact Victoria Alcaraz, Physiotherapist
Phone +34 932275400
Email victoriaalcarazserrano@gmail.com
Status Not yet recruiting
Phase N/A
Start date November 2015

See also
  Status Clinical Trial Phase
Completed NCT01792440 - The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis N/A
Active, not recruiting NCT05523180 - A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life N/A
Completed NCT03218917 - Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis Phase 2
Completed NCT05495243 - Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough Phase 2
Recruiting NCT06237348 - Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH N/A
Completed NCT03056326 - A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects Phase 1
Recruiting NCT04322929 - Roflumilast in Non-CF Bronchiectasis Study (2019) Phase 2
Completed NCT05369624 - Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program N/A
Completed NCT04010799 - A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis Phase 1
Completed NCT03428334 - Roflumilast in Non-CF Bronchiectasis Study Phase 2
Completed NCT04656275 - A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation Phase 1
Not yet recruiting NCT06151366 - Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
Completed NCT02081963 - Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Phase 4
Completed NCT02883101 - The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis N/A
Completed NCT01792427 - Mortality in Non-cystic Fibrosis Bronchiectasis N/A
Recruiting NCT04278040 - Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis Phase 2
Active, not recruiting NCT05006573 - Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis Phase 3
Not yet recruiting NCT06352944 - Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
Recruiting NCT05860803 - Breathing Training and Exercise Capacity in Non-CFB N/A
Recruiting NCT05616221 - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Phase 2